nangibotide
Phase 3- Indications
- Septic shock, COVID-19
Company intelligence / Profile preview
Inotrem
Paris, Île-de-France, Franceinotrem.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 3
01
Overview
Inotrem has successfully reached an agreement with the FDA for a Phase 3 registration trial for nangibotide in septic shock as of January 8, 2024[2].
- Therapeutic areas
- OncologyImmunologyRare DiseasesInfectious Diseases
- Modalities
- PeptidesMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Selexis SA[3]
Beyond the preview
Go deeper on Inotrem.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inotrem.